This is an open trial that included 7 patients with ischemic cardiomyopathy and reduced the ejection fraction (between15% and 35%) administered via intra-myocardial injection with autologous cardiac derived stem cells. Security end points were major cardiac events and efficacy end point was ejection fraction (EF) improvement. At 24 weeks, one of the patients presented a major event (readmission for cardiac insufficiency) and EF improvement was 12%. Oxygen consumption improved 4 ml/kg/min.
Conclusion: intra-myocardial injection of autologous stem cells has a potential restorative effect of EF.
Comment: Despite this open trial that included only a few patients, it opens new lines of research.
Naofumi Takehara
2012-11-06
Original title: The ALCADIA (Autologous Human Cardiac-derived Stem Cell To Treat Ischemic Cardiomyopathy) Trial
